- As a result of HPV vaccination, the number of women getting diagnosed with cervical cancer across the countries under study per year will decrease by 14% from 38,000 in 2016 to 33,000 in 2036.
- Given that screening for cervical cancer is now a mature technology with good uptake, we do not forecast any change in the stage distribution.
- There are 13,200 women eligible for first line drug treatment across the countries covered in this report in 2016.
- Cervical Cancer - Epidemiology - Mature Markets Data
Author(s): Nishant Kumar, MPH; Johnson Olabisi, MBBS, MSc
Nishant is a senior epidemiologist and head of oncology within the epidemiology team at Decision Resources Group. He also covers some CNS diseases, including Alzheimer’s disease and dementia. His key interests are developing interactive patient flows, and modelling disease progression to forecast commercially relevant drug-treatable incident and prevalent populations. Nishant also spends a lot of time collaborating with clients to help answer more specific questions through custom work and consulting projects.
His qualifications include an MSc in Public Health with specialization in epidemiology and statistics from King’s College London, and a BSc in Medical Studies from the University of Birmingham.
Johnson joined Decision Resources Group (DRG) in 2015 and with the Epidemiology team develops epidemiological populations forecasts for different infectious and non-communicable diseases with his particular interests in the oncology space.
Prior to joining DRG, he trained as a community physician where he was involved in primary (patient) care, primary health care and various community research & activities. He has also supervised and coordinated various governmental and non-governmental public health projects. Johnson holds a Masters of Science in Public Health (Health Economics) degree from the London School of Hygiene and Tropical Medicine with a Masters in Epidemiology and Medical Statistics & a Medical degree from the University of Ibadan, Nigeria.